Article citationsMore>>

Saha, P., Regan, M.M., Pagani, O., Francis, P.A., Walley, B.A., Ribi, K., Bernhard, J., Luo, W., Gomez, H.L., Burstein, H.J., Parmar, V., Torres, R., Stewart, J., Bellet, M., Perello, A., Dane, F., Moreira, A., Vorobiof, D., Nottage, M., Price, K.N., Coates, A.S., Goldhirsch, A., Gelber, R.D., Colleoni, M. and Fleming, G.F. (2017) Treatment Efficacy, Adherence, and Quality of Life among Women Younger than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. Journal of Clinical Oncology, 35, 3113-3122.
https://doi.org/10.1200/JCO.2016.72.0946

has been cited by the following article:

• TITLE: Patients with Early-Stage and Estrogen Receptor-Negative Breast Cancers: Young Age Does Link to Poor Outcomes

  AUTHORS: Yanyan Xie, Lv Qing, Yao Wang, Yuting Zhou, Juanjuan Qiu, Qianru Yang, Zhenggui Du

  KEYWORDS: Breast Cancer, Young Age, Intrinsic Subtype, Propensity Score Matching, Prognosis

  JOURNAL NAME: International Journal of Clinical Medicine, Vol.10 No.12, December 27, 2019

  ABSTRACT: Purpose: This study aimed to evaluate whether young adult breast cancer patients have poor outcomes independent of established prognostic factors and analyze differences in prognosis between younger and older patients stratified by tumor subtype. Methods: Of 10,950 breast cancer patients treated at West China Hospital between 1998 and 2017, 741 younger patients (Results: We identified 11 parameters (all P P P P = 0.024] and HR for DFS = 1.301 [95% CI, 1.077 - 1.572; P = 0.006]). When stratified by tumor subtype, younger patients with T1, N0, tumor stage I, G3, estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and Ki67 ≥ 14% had a poor BCSS; in addition, patients with T1, N1, tumor stages I and II, G3, ER-negative, PR-negative, and triple-negative had a poorer DFS than older patients. Conclusion: Young age was an independent prognostic factor for BCSS and DFS in breast cancer patients. The increased risk of relapse was most pronounced in early-stage breast cancer, especially in patients with ER-negative disease.